EX-99.B 3 y44632ex99-b.txt CERTAIN SUPPLEMENTAL INFORMATION 1 EXHIBIT 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
4Q `00 vs. 4Q `99 ------------------------------------------------------------------ TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ---------------------------------------------------------------------------------------------------------- VIOXX N/M $ 700 N/M $ 570 N/M $ 130 VASOTEC / VASERETIC -44% 330 -73% 65 -23% 265 PRINIVIL / PRINZIDE 26% 240 30% 215 0% 25 COZAAR / HYZAAR 29% 530 47% 265 15% 265 MEVACOR -7% 125 0% 105 -33% 20 ZOCOR 14% 1,460 27% 970 -5% 490 AGGRASTAT 20% 30 25% 25 0% 5 SINGULAIR 44% 245 46% 190 38% 55 MAXALT 38% 55 33% 40 50% 15 PROPECIA -10% 45 0% 25 -20% 20 PROSCAR 4% 125 8% 65 0% 60 PRIMAXIN 0% 155 0% 50 0% 105 PEPCID 2% 240 2% 220 0% 20 FOSAMAX 9% 315 11% 210 5% 105 CRIXIVAN/STOCRIN -29% 120 -15% 55 -38% 65 TIMOPTIC/TIMOPTIC XE -24% 65 0% 20 -31% 45 TRUSOPT/COSOPT 0% 100 0% 45 0% 55 HEPATITIS VACCINES 0% 75 0% 70 0% 5 VIRAL VACCINES 5% 115 0% 105 N/M 10 OTHER VACCINES 0% 30 N/M 25 N/M 5
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful 2 MERCK & CO., INC. PRODUCT SALES DETAIL
FULL YEAR 2000 vs. FULL YEAR 1999 ----------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------------------------------------------------------------------------------------------------ VIOXX N/M $2,160 N/M $1,745 N/M $ 415 VASOTEC / VASERETIC -22% 1,790 -28% 705 -18% 1,085 PRINIVIL / PRINZIDE 32% 1,075 35% 965 10% 110 COZAAR / HYZAAR 24% 1,715 24% 770 24% 945 MEVACOR -13% 520 -11% 425 -21% 95 ZOCOR 17% 5,280 30% 3,410 0% 1,870 AGGRASTAT 63% 130 54% 100 N/M 30 SINGULAIR 72% 860 76% 670 58% 190 MAXALT 81% 190 81% 145 80% 45 PROPECIA 5% 195 0% 95 11% 100 PROSCAR 6% 470 15% 230 -2% 240 PRIMAXIN 5% 605 3% 180 6% 425 PEPCID -7% 850 -5% 775 -17% 75 FOSAMAX 22% 1,275 27% 880 13% 395 CRIXIVAN/STOCRIN -20% 530 -21% 210 -20% 320 TIMOPTIC/TIMOPTIC XE -14% 255 -18% 70 -12% 185 TRUSOPT/COSOPT 11% 365 10% 170 11% 195 HEPATITIS VACCINES 15% 345 17% 315 0% 30 VIRAL VACCINES 6% 520 5% 485 17% 35 OTHER VACCINES 14% 80 38% 55 0% 25
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful 3 MERCK & CO., INC. FOURTH QUARTER
4Q `00 4Q `99 % CHG. -------------------------------------------------------------------------------- TOTAL SALES $ 11,467.3 $ 8,963.4 28% ------------ ----------- TOTAL COSTS, EXPENSES, & OTHER $ 8,956.2 $ 6,752.0 ------------ ----------- Materials & Production 6,570.6 4,644.0 Marketing & Administrative 1,774.1 1,588.6 Research & Development 662.4 627.9 Equity Income From Affiliates (145.5) (180.4) Other (Income)/Expense, Net 94.6 71.9 PRE-TAX INCOME $ 2,511.1 $ 2,211.4 TAXES $ 746.7 $ 638.2 TAX RATE 29.7% 28.9% NET INCOME $ 1,764.4 $ 1,573.2 12% EPS - ASSUMING DILUTION $ 0.75 $ 0.66 14% AVG. # SHARES - ASSUMING DILUTION 2,355.8 2,387.5
4Q `00 % CHG. VOL PX FX ------ ------- --- -- -- TOTAL SALES $11,465 28% 24 6 -2 ------- ------- ------- ------- --- Total U.S. and Foreign Sales 5,400 11% 14 1 -4 ------- ------- ------- ------- --- U.S 3,500 20% 17 3 0 Foreign 1,900 -3% 9 -1 -11 Other Medco Sales 6,065 48%
4 MERCK & CO., INC. FULL YEAR
2000 1999 % CHG. -------------------------------------------------------------------------------- TOTAL SALES $ 40,363.2 $ 32,714.0 23% ------------ ------------ TOTAL COSTS, EXPENSES, & OTHER $ 30,539.1 $ 24,094.5 ------------ ------------ Materials & Production 22,443.5 17,534.2 Marketing & Administrative 6,167.7 5,199.9 Research & Development 2,343.8 2,068.3 Acquired Research -- 51.1 Equity Income From Affiliates (764.9) (762.0) Other (Income)/Expense, Net 349.0 3.0 PRE-TAX INCOME $ 9,824.1 $ 8,619.5 TAXES $ 3,002.4 $ 2,729.0 TAX RATE 30.6% 31.7% NET INCOME $ 6,821.7 $ 5,890.5 16% EPS - ASSUMING DILUTION $ 2.90 $ 2.45 18% AVG. # SHARES - ASSUMING DILUTION 2,353.2 2,404.6
2000 % CHG. VOL PX FX ------- -------- ------- -- -- TOTAL SALES $40,365 23% 20 4 -1 ------- ------- ------- -- -- Total U.S. and Foreign Sales 20,225 16% 19 -1 -2 ------- ------- ------- -- -- U.S 12,935 23% 24 -1 0 Foreign 7,290 5% 10 -1 -4 Other Medco Sales 20,140 32%
5 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2000 OTHER (INCOME)/EXPENSE, NET
4Q `00 4Q `99 2000 1999 ------------------------------------------------------------------------------------------------------------- INTEREST INCOME $ (144.2) $ (100.6) $ (470.6) $ (364.7) INTEREST EXPENSE 129.3 97.6 484.4 316.9 EXCHANGE (GAINS)/LOSSES (2.5) (8.4) (34.4) (27.2) MINORITY INTERESTS 77.9 53.8 308.7 222.3 AMORTIZATION OF GOODWILL AND INTANGIBLES 81.0 78.4 319.1 317.4 Other, net (46.9) (48.9) (258.2) (461.7) ------------------------------------------------------ TOTAL $ 94.6 $ 71.9 $ 349.0 $ 3.0 -------------------------------------------------------------------------------------------------------------
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
MERIAL 4Q `00 4Q `99 2000 1999 ------------------------------------------------------------------------------------------------------------- IVOMEC, HEARTGARD, other avermectins $ 130 $ 135 $ 535 $ 565 FRONTLINE 70 45 345 315 Biologicals 80 90 320 340 Other Animal Health 45 65 195 230 Poultry Genetics 50 55 215 230 ------------------------------------------------------ TOTAL MERIAL SALES $ 375 $ 390 $1,610 $1,680 -------------------------------------------------------------------------------------------------------------
AVENTIS PASTEUR-MSD 4Q `00 4Q `99 2000 1999 ------------------------------------------------------------------------------------------------------------- HEPATITIS VACCINES $ 25 $ 40 $135 $160 VIRAL VACCINES 10 20 45 70 Other Vaccines 100 90 360 335 ------------------------------------------------- TOTAL PM-MSD SALES $135 $150 $540 $565 -------------------------------------------------------------------------------------------------------------
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)
2000 1999 % CHG ------------------------------------------------------------------------------------------------------------- FIRST QUARTER 99 94 5% SECOND QUARTER 98 91 8% THIRD QUARTER 120 90 33% FOURTH QUARTER 135 97 39% -------------------------------------- YEAR TO DATE 452 372 22% -------------------------------------------------------------------------------------------------------------